In fact, the systemic administration of two engineered semaphorin molecules, including a NRP1-independent Sema3A superagonist, has been assayed in mice, achieving successful inhibition of tumor growth and metastatic dissemination, without significant adverse effects 16, 55. Here, SEMA3A is linked to neoplasm.